Summary This study was aimed to quantitatively evaluate the effects of topiramate (TPM) on seizure susceptibility and hippocampal peripheral-type benzodiazepine receptors (PBRs) in the kainic acid (KA) model of temporal lobe epilepsy. Male rats were randomized into saline control group, KA group, KA/TPM low dose group and KA/ TPM high dose group. Three weeks after single injection of KA (10 mg kg À1 , sc), the effects of TPM were tested at two doses (10 and 30 mg kg
Introduction
The peripheral-type benzodiazepine receptors (PBRs) are distinct from the central-type benzodiazepine receptors structurally, functionally and pharmacologically. PBRs are a multimeric complex found mainly on the outer mitochondrial membrane of astrocytes. PBRs may also be colocalized with activated microglia in injured brain tissue. PBRs are composed with three subunits, an 18 kDa isoquinoline carboxamide-binding protein, a 34 kDa voltagedependent anion channel and a 30 kDa adenine nucleotide carrier. PBRs have been identified with various physiological functions, such as steroidogenesis, respiration, cell growth and differentiation. Increased PBRs expression was associated with both microglial activation and astrogliosis enhancement. Increased binding sites for PBRs ligands have been described in a wide range of neurological disorders including seizure in both human and animal. 1 In spite of the rapid development of new antiepileptic drugs over the past 20 years, approximately 30% of patients are still refractory to all types of treatments. Thus, the searches for new mechanisms of action that can regulate cellular excitability are vitally needed. Topiramate (TPM) is a widely used antiepileptic agent. In vitro studies suggested that TPM affects neuronal activity and produces its antiepileptic effects by several mechanisms, but which precise mechanism of function is poorly understood. The aim of this study was to measure PBRs expression in hippocampus from KA-induced epileptic rats and test the effects of TPM on seizure threshold and PBRs.
Materials and methods

Materials
TPM was purchased from Janssen Pharmaceutical Ltd. [ 3 H]PK11195 (specific activity, 83.5 Ci/mmol; radiochemical purity, 97%) was purchased from PerkinElmer Life Sciences (Boston, MA). Kainic acid (KA), sucrose, bovine serum albumin, POPOP and unlabelled PK11195 were purchased from Sigma Chemical Co. (St. Louis, MO). PPO and Coomassie brilliant blue G-250 were purchased from Fluka Ltd. (Buchs, Switzerland). Triton X-100 was purchased from Amersham Pharmacia Biotech, Inc. (Uppsala, Sweden). Other chemicals, of reagent grade or better, were from standard commercial suppliers.
Preparation of the reagents
Sucrose buffer (0.25 M sucrose, 1 mM EDTA, 10 mM HEPES-NaOH, pH 7.4) and 0.8 M sucrose solution (0.8 M sucrose, 1 mM EDTA, 10 mM Tris-HCl, pH 7.4) were prepared with distilled water. PK11195 was dissolved in DMSO, and then diluted with phosphatebuffered saline (PBS) to produce test solution. PPO and POPOP dissolved in toluene and Triton X-100 were used as scintillates. TPM and KA were dissolved in saline at suitable concentrations for injection, respectively. All experiments were done under approved animal protocols.
Preparation of the rat model
Male Sprague-Dawley (SD) rats (180-220 g, n = 24) were provided by Beijing Experimental Animal Center (Beijing, China). The rats were housed solitarily in plastic cage under standard conditions (light/dark cycle, 7:00 a.m.-7:00 p.m. lights on), with food and water available ad libitum. Temperature (22 8C) and humidity (60%) were kept constant. All animals were acclimated to their home cages for at least 5 days before testing. Experiments were conducted between 9:00 a.m. and 3:00 p.m. in an experimental room. Animals were randomly divided into saline control group, KA group, KA/TPM low dose group and KA/TPM high dose group. All KA-treated rats (n = 18) received KA (10 mg kg 
Behavioral observation
Occurrence of spontaneous recurrent seizures was video-recorded for 10 h following the initial KA treatment and for 180 min following the second KA treatment in all rats. Seizure threshold was based on the severity of the seizures and the latency from KA injection to seizures. The seizures were divided into five stages according to their severity as described previously.
2 Latency was measured as the time to onset of the first physical sign of seizures, forelimb clonus. Videotapes were reviewed and detected seizures were scored.
Preparation of synaptosomal fractions
Rats were anesthetized with pentobarbital sodium solution (50 mg/kg) and then decapitated after 180 min of behavioral observation. Synaptosomes from hippocampus were purified with a Avanti TM J-30 centrifuge (Bechman) as described by Hajós 3 . The purified synaptosome pellets were frozen on liquid nitrogen and stored at À80 8C until radioligand-binding assay. 
Statistical methods
Data analysis was performed using SPSS Version 10.0 for Windows (SPSS Inc., Chicago, IL). Data obtained from seizure latency and seizure severity scores were expressed as means AE S.D. and analyzed by ANOVA with Scheffe post hoc test. The relationships between indexes were calculated using the Pearson correlation method. The level of significance was defined as p < 0.05.
Results
All KA-treated animals were observed to have spontaneous recurrent motor seizures following the initial and secondary KA injections once epilepsy has developed, while none were observed in the saline-treated controls. Hence, saline-treated control group was ruled out from following statistical analysis for seizure behavior. When compared with KA group, the seizure latency prolonged by 97.3% or 231.2% in KA/TPM low dose group or KA/TPM high dose group, respectively (Fig. 1) .
Seizure stage 5 was first seen about 90 min post-KA (5 mg kg À1 ) injection in KA group. No seizures were recorded in 30 min or 60 min after secondary KA injection in KA/TPM low dose group or KA/TPM high dose group, respectively. In other phase of seizure activity, seizure scores were lower in KA/ TPM low dose group or KA/TPM high dose group than those in KA group, respectively (Fig. 2) (Table 1) .
B max values of PBRs in hippocampal synaptosomes were related to seizure latency and the mean seizure intensity in 180 min after behavioral observation in KA, KA/TPM low dose and KA/TPM high dose groups (Table 2) . No significant correlation was detected concerning K D and seizure threshold in any one of the three groups ( p > 0.05).
By pooling seizure rats of all groups, B max values of PBRs in hippocampal synaptosomes were related to seizure latency (R = À0.852, p < 0.001, n = 18) 360 CF. Chen et al. and maximal seizure intensity (R = 0.838, p < 0.001, n = 18) (Fig. 3) . No significant correlation was found between K D values and seizure threshold parameters ( p > 0.05).
Discussion
Temporal lobe epilepsy (TLE) is one of the most common forms of intractable epilepsy. Frequently associated with these recurrent complex partial seizures is the presence of hippocampal sclerosis (HS) with specific neuronal loss in hippocampus. Injection of KA induces generalized convulsive status epilepticus (SE) in rodents, which represents the initial precipitating injury. After a latent period, adult rats exhibit spontaneous recurrent seizures during the remainder of their life. 5 Because of the relevance of this model to human pathology, the KA model can be used to test the effects of drugs. 6 An association between alterations of PBRs and epilepsy has been proposed. There is conceivably a role for PBRs activation in the pathogenesis of the epileptic process per se. KA-induced epileptic rats showed increased brain densities of PBRs sites. 7 It was suggested that these increases in PBRs sites were either the consequence of the epileptogenic process per se or resulted from the gliosis accompanying neuronal cell loss in hippocampus of epileptic animals. 8, 9 Results of the present study indicated that higher susceptibility to KA-induced seizures were related to increased binding sites of [ 3 H]PK11195 in hippocampus in rats. These findings confirmed and extended those of previous studies which observed increased PBRs sites in the blood mononuclear cells 10 and the brain 11 in patients with epilepsy. Hippocampal sclerosis and hyperexcitability are neuropathological features of human TLE Topiramate effects on seizure susceptibility in kainate-kindled rats that can be reproduced in the KA model of epilepsy in rats. 5, 6, 9 PBRs was mainly found on the membrane of astrocytes. 1 Immunohistochemical studies revealed increased PBRs immunolabeling in CA1 subfield of TLE patients with hippocampal sclerosis. The increased immunolabeling was particularly localized on astrocytic elements suggesting that the increased PBRs signal was the consequence of astrogliosis which accompanied neuronal cell loss in TLE.
11 Similar findings of increased PBRs sites coincident with astrocytic proliferation in the presence of neuronal loss were previously reported in Alzheimer's disease and Wernicke's encephalopathy. 1 On the other hand, PBRs were also colocalized with activated microglia in injured brain tissue. Other disorders, such as multiple sclerosis 12 and strokeinduced brain injury, 13 have been described with increased PBRs sites coinciding with activating microglia rather than astrocytes. KA treatment induces Ammon's horn sclerosis, which is characterized by neurons degeneration and reactive gliosis. The glial reaction consists of a proliferation and hypertrophy of astrocytes and microglia macrophages. Novel findings in the present study of a correlation between the increased PBRs sites with seizure latency and seizure severity in all seizure rats suggest that PBRs binding in hippocampus was related to the increased long-term susceptibility to seizures. It has been reported that pre-treatment with the PK11195, a specific PBRs antagonist, can attenuate the occurrence of seizures. 7 Nefiracetam may inhibit spontaneous seizures in EL mice through interacting with PBRs.
14 Together with these results indicate that PBRs could represent a novel target for antiepileptic drug development. Nonetheless, the potential action of PBRs on seizures has not been used in animal models to screen antiepileptic drugs that block these receptors.
TPM [2,3:4,5-bis-O-(1-methylethylidene)-36-Dfructopyranose sulfamate] is a structurally novel antiepileptic drug that is approved for use in the treatment of refractory partial-onset seizures in adults, partial-onset seizures in children, and generalized tonic-clonic seizures of nonfocal origin. 15 Several cellular mechanisms have been proposed for the therapeutic effects of TPM, including (1) activity-dependent attenuation of voltage-dependent sodium and calcium currents; (2) potentiation of GABA A -receptor-mediated currents; (3) inhibition of AMPA/kainate receptors; and (4) TPM has a weak inhibitory effect on some carbonic anhydrase isoenzymes. 16 The relative importance of any of these mechanisms in the clinical activity of TPM is not well defined. The experiments reported here showed that TPM has powerful ameliorating effects, accompanied by PBRs decreases, on KAinduced seizures in a dose-dependent manner. Surprisingly, PBRs expression in hippocampus returned to normal level after TPM treatment in 30 mg kg À1 in rats. Findings in the present study suggest that the neuronal activity and antiepileptic effects of TPM may be functioned through PBRs mechanisms. At the same time, our results, as shown in Table 1 , also indicated that TPM did not change the affinity of PBRs, but increased the number of binding sites in hippocampus synaptosomal membranes. With the knowledge of the pharmacological properties of TPM, several of its mechanisms of action could be expected to have neuroprotective properties. TPM exhibits neuroprotective properties in several models of injury such as global ischemia, 17 focal ischemia, 18 SE 19, 20 or other neurological and systemic diseases. 21 Most patients with TLE, the most common type of epilepsy, showed pronounced loss of neurons in limbic brain regions, including the hippocampus. The massive neurodegeneration in the hippocampus is known as HS, and is considered one of the hallmarks of this type of difficult-to-treat epilepsy. Previous studies revealed that single (40 mg kg À1 ) or repeated doses of TPM (30 mg kg À1 ) 1) given after experimental seizures can prevent the increase in susceptibility to KA seizure-induced hippocampal neuronal injury in rats and this protection occurs independent of its anticonvulsant action. 22, 23 Neuroprotective properties of TPM could explain the present results.
In conclusion, higher profile of the PBRs binding sites in hippocampus synaptosomal membranes is associated with the increase in susceptibility to KAinduced seizures in rats. Inhibition of PBRs may represent one mechanism through which TPM increases seizure threshold.
